Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Baxter Innovations GmbH

Home Clinical Trial Sponsors and OrganizationsBaxter Innovations GmbH

Baxter Innovations GmbH

ACTIVE

Austriawww.baxter.comSubsidiary

Part of Baxter International, Inc.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

148

143 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

44

29.7%

Phase 2

1

0.7%

Phase 2/3

1

0.7%

Trial Status Distribution

Active, not recruiting

143

96.6%

Completed

5

3.4%

Clinical Trials

Trials sponsored by this organization (148)

A study to compare a single dose of M923, EU-sourced Humira or US-sourced Humira in healthy volunteers

Feb 2015324 participants

A study of the pharmacokinetics, efficacy, safety, and immunogenicity of BAX-855 Administered for Prevention of Bleeding in PreviouslyTreated Pediatric Patients with Severe Hemophilia A (a blood clotting disorder).

Active, not recruiting

Feb 201550 participants

A study to evaluate the safety and effectiveness of the Recombinant Von Willebrand Factor administred with or without Advate for subjects with severe von Willebrand disease (a hereditary coagulation abnormality) who will undergo major,minor or oral surgery procedures.

Active, not recruiting

Dec 201415 participants

A study to evaluate the safety and effectiveness of the Recombinant Von Willebrand Factor administred with or without Advate for subjects with severe von Willebrand disease (a hereditary coagulation abnormality) who will undergo major,minor or oral surgery procedures.

Active, not recruiting

Nov 201415 participants

A study of the pharmacokinetics, efficacy, safety, and immunogenicity of BAX-855 Administered for Prevention of Bleeding in PreviouslyTreated Pediatric Patients with Severe Hemophilia A (a blood clotting disorder).

Active, not recruiting

Oct 201450 participants

A study of the Safety and Effectiveness of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prevention and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A (a blood clotting disorder).

Active, not recruiting

Jul 2014138 participants

A study of the pharmacokinetics, efficacy, safety, and immunogenicity of BAX-855 Administered for Prevention of Bleeding in PreviouslyTreated Pediatric Patients with Severe Hemophilia A (a blood clotting disorder).

Active, not recruiting

Jul 201466 participants

BAX 326 (recombinant cogulation factor IX): Continuation of a study of safety and effectiveness of the product in previously treated patients with severe or moderately severe hemophilia B.

Active, not recruiting

Jun 2014117 participants

Page 1 of 19

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials148
Approvals
News

Back to Organizations